S. Karger AG

SHERPA: Unknown

People

  1. Abou-Alfa
    Abou-Alfa
  2. Janjigian
    Janjigian
  3. O'Reilly
    O'Reilly
  4. Ilson
    Ilson
  5. Saltz
    Saltz
  6. Cercek Hanjis
    Cercek Hanjis
  7. Molena
    Molena
  8. Raj
    Raj
  9. Bajorin
    Bajorin
  10. Bodei
    Bodei

Groups

  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)
  7. Weinberg Fellows (4)
  8. Graduate Medical Education (3)
  9. Biostatistics Service (2)
  10. Body Imaging Service (2)
Search Within
  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (9)
Groups
  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)

More Groups

People
  1. Ghassan Abou-Alfa (18)
  2. Yelena Janjigian (12)
  3. Eileen O'Reilly (8)
  4. David Ilson (4)
  5. Diane Reidy (4)
  6. Andrea Cercek Hanjis (3)

More People

Years
  1. 2024 (7)
  2. 2023 (8)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (10)
  6. 2019 (7)

More Years

Publications
  1. Oncology Research and Treatment (46)
  2. Neuroendocrinology (4)
  3. Oncology (4)
  4. Onkologie (2)
  5. Case Reports in Oncology (1)

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW
    Meeting Abstract

    Lordick, F.; Xu, R. H.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Galle, P. R.; Crysler, O.; Yarchoan, M.; Furuse, J.; Sukeepaisarnjaroen, W.; Thinh, N. T.; Masi, G.; Lim, H. Y.; Varela, M.; Gupta, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Meeting Abstract

    Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Goetze, T.; Melisi, D.; Macarulla, T.; Cid, R. A. P.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Durable response after olaparib treatment for perihilar cholangiocarcinoma with germline BRCA2 mutation
    Journal Article

    Costa, B. A.; Tallón de Lara, P.; Park, W.; Keane, F.; Harding, J. J.; Khalil, D. N.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
    Meeting Abstract

    Arnold, D.; Hammel, P.; Golan, T.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Stein, A.; Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; DI Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Erweiterte gesamtüberlebensergebnisse aus der POLO-studie zur aktiven erhaltungstherapie mit olaparib bei patienten mit metastasiertem bauchspeicheldrüsenkrebs und einer keimbahn-BRCA-mutation
    Meeting Abstract

    Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dosiseskalations- und dosiserweiterungsstudie mit trastuzumab-deruxtecan(T-DXd)-monotherapie und -Kombinationen bei patienten mit fortgeschrittenem/ metastasiertem HER2+-magenkarzinom (GC) / adenokarzinom des gastroösophagealen überganges (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Rha, S. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; Di Bartolomeo, M.; Díez García, M.; Haj Mohammad, N.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save